Cingulate Inc. (NASDAQ: CING) has recently been in the spotlight following the initiation of coverage by Stonegate Capital Partners, highlighting the company’s progress with its lead ADHD asset, CTx-1301. This development is crucial as it underscores the potential of CTx-1301 to address significant gaps in ADHD treatment, offering a once-daily stimulant therapy with rapid onset and sustained efficacy throughout the day. The ADHD market, estimated at $22 billion in the U.S., is in dire need of innovative treatments that can overcome the limitations of current therapies, which often require booster doses and lack flexibility in administration. The company’s recent Phase 3 pediatric study results for CTx-1301 have been promising, with all tested doses showing statistically significant improvements on the ADHD-RS
This contant was orignally distributed by Evertise Digital. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cingulate Inc. Advances ADHD Treatment with CTx-1301, Eyes FDA Approval.
